Literature DB >> 27658511

An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.

Hayate Javed1, Mohammad Amjad Kamal, Shreesh Ojha2.   

Abstract

Parkinson's disease (PD) is a devastating and progressive movement disorder characterized by symptoms of muscles rigidity, tremor, postural instability and slow physical movements. Biochemically, PD is characterized by lack of dopamine production and its action due to loss of dopaminergic neurons and neuropathologically by the presence of intracytoplasmic inclusions known as Lewy bodies, which mainly consist of presynaptic neuronal protein, α-synuclein (α-syn). It is believed that alteration in α-syn homeostasis leads to increased accumulation and aggregation of α-syn in Lewy body. Based on the important role of α-syn from pathogenesis to therapeutics, the recent researches are mainly focused on deciphering the critical role of α-syn at advanced level. Being a major protein in Lewy body that has a key role in pathogenesis of PD, several model systems including immortalized cell lines (SH-SY5Y), primary neuronal cultures, yeast (saccharomyces cerevisiae), drosophila (fruit flies), nematodes (Caenorhabditis elegans) and rodents are being employed to understand the PD pathogenesis and treatment. In order to study the etiopathogensis and develop novel therapeutic target for α -syn aggregation, majority of investigators rely on toxin (rotenone, 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine, 6-hydroxydopamine, paraquat)-induced animal models of PD as a tool for basic research. Whereas, cell and tissue based models are mostly utilized to elucidate the mechanistic and molecular pathways underlying the α -syn induced toxicity and therapeutic approaches in PD. Gene modified mouse models based on α-syn expression are fascinating for modeling familial PD and toxin induced models provide a suitable approach for sporadic PD. The purpose of this review is to provide a summary and a critical review of the involvement of α-syn in various in vitro and in vivo models of PD based on use of neurotoxins as well as genetic modifications.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27658511     DOI: 10.2174/1871527315666160920160512

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  6 in total

1.  Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress.

Authors:  Hui-Ju Huang; Yi-Ting Wang; Hui-Ching Lin; Yi-Hsuan Lee; Anya Maan-Yuh Lin
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

Review 2.  Animal models of α-synucleinopathy for Parkinson disease drug development.

Authors:  James B Koprich; Lorraine V Kalia; Jonathan M Brotchie
Journal:  Nat Rev Neurosci       Date:  2017-07-13       Impact factor: 34.870

3.  Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.

Authors:  Vinod Kumar; Deepali Singh; Brajesh Kumar Singh; Shweta Singh; Namrata Mittra; Rakesh Roshan Jha; Devendra Kumar Patel; Chetna Singh
Journal:  Mol Cell Biochem       Date:  2017-12-02       Impact factor: 3.396

4.  K284-6111 prevents the amyloid beta-induced neuroinflammation and impairment of recognition memory through inhibition of NF-κB-mediated CHI3L1 expression.

Authors:  Ji Yeon Choi; In Jun Yeo; Ki Cheon Kim; Won Rack Choi; Jae-Kyung Jung; Sang-Bae Han; Jin Tae Hong
Journal:  J Neuroinflammation       Date:  2018-08-11       Impact factor: 8.322

5.  Brain-Targeted Biomimetic Nanodecoys with Neuroprotective Effects for Precise Therapy of Parkinson's Disease.

Authors:  Yao Liu; Jingshan Luo; Yujing Liu; Wen Liu; Guangtao Yu; Yuting Huang; Yu Yang; Xiaojia Chen; Tongkai Chen
Journal:  ACS Cent Sci       Date:  2022-09-13       Impact factor: 18.728

6.  Minimotifs dysfunction is pervasive in neurodegenerative disorders.

Authors:  Surbhi Sharma; Richard J Young; Jingchun Chen; Xiangning Chen; Edwin C Oh; Martin R Schiller
Journal:  Alzheimers Dement (N Y)       Date:  2018-07-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.